Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture
- 1 July 1997
- journal article
- clinical trial
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 139 (7) , 606-612
- https://doi.org/10.1007/bf01411994
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Performance of sulfhydryl boron hydride in patients with grade III and IV astrocytoma: a basis for boron neutron capture therapyJournal of Neurosurgery, 1995
- Subcellular boron-10 localization in glioblastoma for boron neutron capture therapy with Na2B12H11SHJournal of Neurosurgery, 1994
- Present status and perspectives of boron neutron capture therapyRadiotherapy and Oncology, 1994
- Clinical phase-I study of NA2B12H11SH (BSH) in patients with malignant glioma as precondition for boron neutron capture therapy (BNCT)International Journal of Radiation Oncology*Biology*Physics, 1994
- Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapyInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Clinical Experience with Bnct for Malignant Brain TumorsPublished by Springer Nature ,1993
- Boron Neutron Capture TherapyPublished by Springer Nature ,1992
- A HISTORY OF BORON NEUTRON CAPTURE THERAPY OF BRAIN TUMOURSBrain, 1991
- Current status of 10B-neutron capture therapy: Enhancement of tumor dose via beam filtration and dose rate, and the effects of these parameters on minimum boron content: A theoretical evaluationInternational Journal of Radiation Oncology*Biology*Physics, 1985
- Penetration of Brain and Brain Tumor. VII. Tumor-Binding Sulfhydryl Boron CompoundsJournal of Medicinal Chemistry, 1967